Simvastatin addition to improve symptoms, cognition and metabolic syndrome in patients with recent-onset schizophrenia.

The primary objective of this trial is to investigate the proposed beneficial effect of simvastatin as compared to placebo when given in addition to antipsychotic medication on symptom severity as measured through Positive and Negative Syndrome Scale (PANSS).